NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaResearch in context

Summary: Background: The prognosis for patients with poorly-differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy with no standard second-line (2L) treatment. Methods: Patient...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Mairéad G. McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sharmila Sothi, Alan Anthoney, Christopher Bell, Alkesh Patel, Jamie B. Oughton, David A. Cairns, Wasat Mansoor, Angela Lamarca, Richard A. Hubner, Juan W. Valle
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2023-06-01
Edice:	EClinicalMedicine
Témata:	Neuroendocrine carcinoma Second-line treatment Liposomal irinotecan Docetaxel Quality of life
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S258953702300192X
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!